These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 12468151)
1. The role of chemotherapy (CT) and supportive care (SC) in advanced non-small cell lung cancer (NSCLC). Thatcher N Lung Cancer; 2002 Dec; 38 Suppl 3():S71-3. PubMed ID: 12468151 [No Abstract] [Full Text] [Related]
2. An unusual case of gemcitabine-induced radiation recall. Squire S; Chan M; Feller E; Mega A; Gold R Am J Clin Oncol; 2006 Dec; 29(6):636. PubMed ID: 17149004 [No Abstract] [Full Text] [Related]
3. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Gong W; Zhang X; Wu J; Chen L; Li L; Sun J; Lv Y; Wei X; Du Y; Jin H; Dong J Lung Cancer; 2012 Mar; 75(3):374-80. PubMed ID: 21889227 [TBL] [Abstract][Full Text] [Related]
4. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer. Zwitter M; Kovac V; Smrdel U; Strojan P J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933 [TBL] [Abstract][Full Text] [Related]
6. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis. Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of gemcitabine as second-line chemotherapy in non-small cell lung cancer. Cok G; Göksel T; Soyer S; Aysan T Tuberk Toraks; 2008; 56(1):74-80. PubMed ID: 18330758 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. Reynolds C; Obasaju C; Schell MJ; Li X; Zheng Z; Boulware D; Caton JR; Demarco LC; O'Rourke MA; Shaw Wright G; Boehm KA; Asmar L; Bromund J; Peng G; Monberg MJ; Bepler G J Clin Oncol; 2009 Dec; 27(34):5808-15. PubMed ID: 19884554 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Li L; Schaid DJ; Fridley BL; Kalari KR; Jenkins GD; Abo RP; Batzler A; Moon I; Pelleymounter L; Eckloff BW; Wieben ED; Sun Z; Yang P; Wang L Pharmacogenet Genomics; 2012 Feb; 22(2):105-16. PubMed ID: 22173087 [TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904 [TBL] [Abstract][Full Text] [Related]
12. [Gemcitabine and radiotherapy for the future]. Girard N; Mornex F Cancer Radiother; 2007 Jun; 11(4):167-8. PubMed ID: 17601763 [No Abstract] [Full Text] [Related]
13. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC). Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086 [TBL] [Abstract][Full Text] [Related]
14. Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301). Des Guetz G; Landre T; Westeel V; Milleron B; Vaylet F; Urban T; Barlesi F; Souquet PJ; Debieuvre D; Braun D; Fraboulet G; Monnet I; Uzzan B; Molinier O; Morin F; Moro-Sibilot D; Morère JF J Geriatr Oncol; 2015 May; 6(3):233-40. PubMed ID: 25698450 [TBL] [Abstract][Full Text] [Related]
16. Quality-of-life assessment in phase III clinical trials of gemcitabine in non-small-cell lung cancer. Reynolds JK; Levien TL Drugs Aging; 2008; 25(11):893-911. PubMed ID: 18947258 [TBL] [Abstract][Full Text] [Related]
17. [Advances of drug resistance marker of gemcitabine for non-small cell lung cancer]. Chen Y; Qian X; Liu B Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):421-8. PubMed ID: 21569648 [TBL] [Abstract][Full Text] [Related]
18. [Analysis of factors associated with quality of life for older adult patients with non-small cell lung cancer receiving outpatient gemcitabine therapy as an alternative inpatient therapy]. Ishiura Y; Yamamoto H; Terasaki Y; Ishida Y; Fukushima W; Hirosawa H; Izumi R; Tanikawa F; Hayase H; Maruyama K; Obata C; Ishikawa M; Kasahara K; Fujimura M Gan To Kagaku Ryoho; 2009 Dec; 36(13):2565-9. PubMed ID: 20009456 [TBL] [Abstract][Full Text] [Related]
19. Gemcitabine-induced acute eosinophilic pneumonia. Kim YH; Mishima M; Yoshizawa A J Thorac Oncol; 2010 Aug; 5(8):1308-9. PubMed ID: 20661093 [No Abstract] [Full Text] [Related]
20. Low-dose gemcitabine in long infusion: when less is more. Zwitter M Indian J Cancer; 2012; 49(2):199-201. PubMed ID: 23107970 [No Abstract] [Full Text] [Related] [Next] [New Search]